caa a22 4500 605490325 CHVBK 20210128100504.0 cr unu---uuuuu 210128e20150201xx s 000 0 eng 10.1007/s10147-014-0700-8 doi (NATIONALLICENCE)springer-10.1007/s10147-014-0700-8 The impact of a fourteen-gene molecular assay on physician treatment decisions in non-small-cell lung cancer [Elektronische Daten] [Shane Dormady, Michael Broder, Girish Putcha, Robert Dumanois, Alison DeCristofaro, Eunice Chang, Paul Billings, Thierry Jahan] Background: Five-year survival in early-stage, non-squamous, non-small-cell lung cancer (NSCLC) remains poor compared with other solid tumors, even after complete resection. Post-operative management depends on prognostic staging to identify individuals at highest risk for death, and therefore with the greatest need for further intervention. A 14-gene quantitative RT-PCR test successfully differentiates stage I-III NSCLC patients who are at high-, intermediate-, or low-risk for 5-year mortality. This study assesses the impact of the assay's prognostic information on physician decisions regarding adjuvant chemotherapy. Methods: We invited 115 physicians who ordered the test to participate in an on-line survey. The primary outcome measure was the proportion of patients with different pre- and post-test chemotherapy recommendations. Results: Fifty-eight physicians (50%) completed the survey on 120 stage I or II NSCLC patients. Ninety-one patients (76%) had stage I lung cancer; 27 (23%), 39 (33%), and 54 (45%) patients had low-, intermediate-, and high-risk scores, respectively. Physicians' chemotherapy recommendations were changed post-testing in 37 patients (30.8%, 95% CI 22.7-39.9%). High-risk patients were more likely to have a change in treatment recommendation (44.4%, 95% CI 30.9-58.6%) than low risk patients (3.7%, 95% CI 0.1-19.0%); a substantial number of changes were observed in both stage I (33.0%, 95% CI 23.5-43.6%) and stage II (24.1%, 95% CI 10.3-43.5%). Conclusions: Our data show that the assay resulted in a significant impact on physician treatment decisions in early-stage NSCLC, and that the nature of treatment changes generally correlated with the test's assessment of risk. Japan Society of Clinical Oncology, 2014 Lung cancer nationallicence Chemotherapy nationallicence Medical decision-making nationallicence Dormady Shane Valley Medical Oncology Consultants, 2940 Whipple Ave., Redwood City, CA, USA aut Broder Michael Partnership for Health Analytic Research, LLC, 280 South Beverly Drive, Suite 404, 90212, Beverly Hills, CA, USA aut Putcha Girish Life Technologies Corporation, 5791 Van Allen Way, 92008, Carlsbad, CA, USA aut Dumanois Robert Life Technologies Corporation, 5791 Van Allen Way, 92008, Carlsbad, CA, USA aut DeCristofaro Alison Partnership for Health Analytic Research, LLC, 280 South Beverly Drive, Suite 404, 90212, Beverly Hills, CA, USA aut Chang Eunice Partnership for Health Analytic Research, LLC, 280 South Beverly Drive, Suite 404, 90212, Beverly Hills, CA, USA aut Billings Paul Life Technologies Corporation, 5791 Van Allen Way, 92008, Carlsbad, CA, USA aut Jahan Thierry Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, Box 1724, 94143-1724, San Francisco, CA, USA aut International Journal of Clinical Oncology Springer Japan 20/1(2015-02-01), 59-69 1341-9625 20:1<59 2015 20 10147 https://doi.org/10.1007/s10147-014-0700-8 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s10147-014-0700-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Dormady Shane Valley Medical Oncology Consultants, 2940 Whipple Ave., Redwood City, CA, USA aut NATIONALLICENCE 700 1- Broder Michael Partnership for Health Analytic Research, LLC, 280 South Beverly Drive, Suite 404, 90212, Beverly Hills, CA, USA aut NATIONALLICENCE 700 1- Putcha Girish Life Technologies Corporation, 5791 Van Allen Way, 92008, Carlsbad, CA, USA aut NATIONALLICENCE 700 1- Dumanois Robert Life Technologies Corporation, 5791 Van Allen Way, 92008, Carlsbad, CA, USA aut NATIONALLICENCE 700 1- DeCristofaro Alison Partnership for Health Analytic Research, LLC, 280 South Beverly Drive, Suite 404, 90212, Beverly Hills, CA, USA aut NATIONALLICENCE 700 1- Chang Eunice Partnership for Health Analytic Research, LLC, 280 South Beverly Drive, Suite 404, 90212, Beverly Hills, CA, USA aut NATIONALLICENCE 700 1- Billings Paul Life Technologies Corporation, 5791 Van Allen Way, 92008, Carlsbad, CA, USA aut NATIONALLICENCE 700 1- Jahan Thierry Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, Box 1724, 94143-1724, San Francisco, CA, USA aut NATIONALLICENCE 773 0- International Journal of Clinical Oncology Springer Japan 20/1(2015-02-01), 59-69 1341-9625 20:1<59 2015 20 10147